Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Shuttle Pharmaceuticals Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Shuttle Pharmaceuticals Holdings şirketinin kazançları yıllık ortalama -41.2% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.7% oranında arttı.

Anahtar bilgiler

-41.2%

Kazanç büyüme oranı

-35.8%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-897.8%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Shuttle Pharma awarded new patents for its radiation sensitizing technology platform

Sep 15

Gelir ve Gider Dağılımı

Shuttle Pharmaceuticals Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:SHPH Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	-7	3	3
31 Mar 24	-7	3	3
31 Dec 23	-7	2	4
30 Sep 23	-6	2	4
30 Jun 23	-5	2	3
31 Mar 23	-3	2	2
31 Dec 22	-3	1	1
30 Sep 22	-3	1	1
30 Jun 22	-2	1	1
31 Mar 22	-2	1	1
31 Dec 21	-1	1	1
31 Dec 20	-1	0	0
30 Jun 19	-1	1	0
31 Mar 19	-1	1	0
31 Dec 18	-1	1	0
30 Sep 18	0	0	0
30 Jun 18	0	0	0
31 Mar 18	0	0	0
31 Dec 17	0	0	0
30 Sep 17	0	0	0
30 Jun 17	0	0	0
31 Mar 17	0	0	0
31 Dec 16	0	0	0
30 Sep 16	0	0	0
31 Dec 15	0	0	0

Kaliteli Kazançlar: SHPH şu anda kârlı değil.

Büyüyen Kar Marjı: SHPH şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SHPH kârlı değildir ve zararlar son 5 yılda yılda 41.2% oranında artmıştır.

Büyüme Hızlandırma: SHPH 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: SHPH kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 0.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: SHPH hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -897.83% ) sahiptir.

Shuttle Pharmaceuticals Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.

Shuttle Pharmaceuticals Holdings, Inc. Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

Shuttle Pharmaceuticals Provides Regains Compliance with Nasdaq Listing Rule 5250(c)

Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing

Shuttle Pharmaceuticals Holdings, Inc. Announces Publication of A Manuscript Reporting on the Ability of One of the Company’s HDAC Inhibitor Pre-Clinical Assets, SP-1-303

Shuttle Pharmaceuticals Holdings, Inc. Announces Chief Financial Officer Changes

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Jul 31, 2024

New major risk - Financial position

New major risk - Financial position

New minor risk - Share price stability

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

New minor risk - Share price stability

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Dec 18, 2023

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Dec 18, 2023

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. Expands Patent Coverage on HDAC Inhibitor Platform

Shuttle Pharmaceuticals Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

New major risk - Financial position

Shuttle Pharmaceuticals Holdings Files Form 10-Q with the Securities and Exchange Commission and Regains Compliance with the Nasdaq Listing Rules

Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing

Shuttle Pharmaceuticals Holdings, Inc. announced that it has received $4 million in funding from Ayrton Capital LLC

Shuttle Pharmaceuticals Holdings, Inc. Announces the Publication of Manuscript Discussing Immune Responses Taking Place in Patients After Radiation Therapy for Cancer

Insufficient new directors

Shuttle Pharmaceuticals Holdings, Inc. Appoints Bette Jacobs to Its Board of Directors

Shuttle Pharmaceuticals Holdings, Inc. Receives New HDAC Inhibitor Patents for Cancer Treatment

Shuttle Pharma awarded new patents for its radiation sensitizing technology platform

Shuttle Pharmaceuticals Holdings, Inc. has completed an IPO in the amount of $9.96034 million.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin